EQS-News: Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
08.06.2023 / 16:21 CET/CEST
The issuer is solely responsible for the content of this announcement.
Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
PARIS, France, June 6, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on June 5, 2023, which was chaired by Marc de Garidel, CEO of Abivax and interim Chairman of the Board of Directors.
The shareholders have adopted all the resolutions approved by the Board of Directors and, in particular, the financial statements for the 2022 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of Directors related to financial transactions.
Shareholders also ratified the cooptation of Mr. Marc de Garidel as Board member and approved the appointment of Agili(3f) as co-statutory auditors for a period of six financial years.
Details on the vote results will be available on the Company’s website.
*****
Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
Contacts
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63
Investors
LifeSci Advisors
Ligia Vela-Reid
lvela-reid@lifesciadvisors.com
+44 7413 825310
Press Relations Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22
Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24 Public Relations France
Primatice
Thomas Roborel de Climens
thomasdeclimens@primatice.com
+33 6 78 12 97 95 Public Relations USA
Rooney Partners LLC
Jeanene Timberlake
jtimberlake@rooneypartners.com
+1 646 770 8858
08.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
1650705 08.06.2023 CET/CEST